Clofibrate


Curated chemical-disease associations from CTD
Disease IDDisease nameReference
MESH:D001145 Arrhythmias, Cardiac PMID:3547004; PMID:5773125
MESH:D001416 Back Pain PMID:55557; PMID:7437867
MESH:D001749 Urinary Bladder Neoplasms PMID:2125992
MESH:D001778 Blood Coagulation Disorders PMID:19483382
MESH:D002637 Chest Pain PMID:3142389
MESH:D002764 Cholecystitis PMID:3547004
MESH:D002769 Cholelithiasis PMID:3547004; PMID:7157849
MESH:D004211 Disseminated Intravascular Coagulation PMID:6728507
MESH:D004417 Dyspnea PMID:3515563
MESH:D004487 Edema PMID:661938
MESH:D004620 Embolism, Fat PMID:7206007
MESH:D005076 Exanthema PMID:7437867
MESH:D005234 Fatty Liver PMID:19224547
MESH:D005770 Gastrointestinal Neoplasms PMID:3547004
MESH:D006099 Granuloma PMID:661938
MESH:D006331 Heart Diseases PMID:6728507
MESH:D006470 Hemorrhage PMID:7206007
MESH:D006528 Carcinoma, Hepatocellular PMID:10478332; PMID:15509519; PMID:16470657; PMID:1740018; PMID:3240312; PMID:508572
MESH:D006529 Hepatomegaly PMID:11969379; PMID:12851107; PMID:15033592; PMID:18670166; PMID:19952500; PMID:20637823; PMID:22008526; PMID:22008536; PMID:22467018; PMID:2260096; PMID:28108177; PMID:28495587; PMID:32741898; PMID:33549593; PMID:33983380; PMID:3590187; PMID:3625448; PMID:6424681; PMID:6606240; PMID:661938; PMID:8700121; PMID:9007043
MESH:D006937 Hypercholesterolemia PMID:1175893
MESH:D006959 Hyperoxaluria PMID:9030817
MESH:D006965 Hyperplasia PMID:9207284
MESH:D006984 Hypertrophy PMID:28495587; PMID:633072
MESH:D007172 Erectile Dysfunction PMID:50074
MESH:D007889 Leiomyoma PMID:508572
MESH:D008107 Liver Diseases PMID:10550479; PMID:10569642; PMID:8994295; PMID:9207284
MESH:D008113 Liver Neoplasms PMID:22084566; PMID:25058030; PMID:28108177; PMID:28899750
MESH:D008114 Liver Neoplasms, Experimental PMID:10600397; PMID:16800819; PMID:17636249; PMID:21035526; PMID:21214675; PMID:6850573; PMID:728341; PMID:8055661; PMID:8597128; PMID:8968061
MESH:D009133 Muscular Atrophy PMID:6511338
MESH:D009135 Muscular Diseases PMID:1307471; PMID:2089182; PMID:4126124; PMID:448390; PMID:532624; PMID:6468459; PMID:729726; PMID:7439122; PMID:7458683; PMID:81288; PMID:995042
MESH:D009202 Cardiomyopathies PMID:846520
MESH:D009212 Myoglobinuria PMID:846520
MESH:D009220 Myositis PMID:3547004
MESH:D009325 Nausea PMID:7437867
MESH:D009336 Necrosis PMID:16465232; PMID:661938
MESH:D009395 Nephritis, Interstitial PMID:7437867
MESH:D009461 Neurologic Manifestations PMID:1307471
MESH:D009468 Neuromuscular Diseases PMID:62135
MESH:D010146 Pain PMID:204061; PMID:2089182; PMID:4115569; PMID:4126124; PMID:63766
MESH:D010190 Pancreatic Neoplasms PMID:508572
MESH:D011141 Polyuria PMID:4115569
MESH:D011230 Precancerous Conditions PMID:20180811; PMID:21214675; PMID:2869179; PMID:8968061
MESH:D011654 Pulmonary Edema PMID:7206007
MESH:D013375 Substance Withdrawal Syndrome PMID:532624
MESH:D014511 Uremia PMID:55557
MESH:D014839 Vomiting PMID:55557
MESH:D017240 Mitochondrial Myopathies PMID:17562484; PMID:4072624
MESH:D018223 Dermatofibrosarcoma PMID:508572
MESH:D018248 Adenoma, Liver Cell PMID:15509519
MESH:D018908 Muscle Weakness PMID:3515563; PMID:54800; PMID:62135; PMID:63766; PMID:6511338; PMID:799549
MESH:D020879 Neuromuscular Manifestations PMID:63766
MESH:D028361 Mitochondrial Diseases PMID:17499714
MESH:D042882 Gallstones PMID:1175893; PMID:1536697
MESH:D056486 Chemical and Drug Induced Liver Injury PMID:28495587; PMID:33814510; PMID:3714094
MESH:D058186 Acute Kidney Injury PMID:55557; PMID:7437867

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.